0.0100CAD0.00%Mkt Cap: 540000 CADP/E: —Last update: 2026-05-25
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer tr…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap540.00K CAD
Enterprise Value3.70M CAD
Revenue (TTM)1.51M CAD
Gross Profit513.68K CAD
Net Income (TTM)-499.21K CAD
Revenue/Share0.0280 CAD
Last Price0.0100 CAD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-16.46
EV/Revenue2.45
P/S0.36
P/B-0.23
EPS (TTM)-0.01
EPS (Forward)—
52W Range
0.01000% of range0.0400
52W High0.0400 CAD
52W Low0.0100 CAD
Profitability
Gross Margin38.06%
Oper. Margin-68.31%
EBITDA Margin-14.92%
Profit Margin-36.99%
ROE19.42%
ROA-40.12%
Growth
Revenue Growth1129.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-611.03K CAD
CapEx (TTM)—
FCF Margin-48.81%
FCF Yield-136.10%
Net Debt3.16M CAD
Net Debt/EBITDA-14.05
Balance Sheet
Debt/Equity-1.34
Current Ratio0.11
Quick Ratio0.04
Book Value/Sh-0.0440 CAD
Cash/Share0.0010 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.54.00M
Float13.55M
Insiders74.90%
Institutions0.00%
Short Interest
Short Ratio0.0d
Short % Out.0.00%
Shares Short571
Short (prev mo.)988
Technical
SMA 500.0139 (-28.1%)
SMA 2000.0178 (-43.7%)
Beta1.34
S&P 52W Chg28.31%
Avg Vol (30d)667
Avg Vol (10d)0
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—